ImmuPharma plc (LON:IMM – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of GBX 4.18 and traded as low as GBX 3.25. ImmuPharma shares last traded at GBX 3.50, with a volume of 1,174,835 shares.
ImmuPharma Price Performance
The stock’s fifty day simple moving average is GBX 3.71 and its 200-day simple moving average is GBX 4.17. The stock has a market cap of £20.59 million, a P/E ratio of -8.92 and a beta of 3.01.
ImmuPharma (LON:IMM – Get Free Report) last issued its earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. Analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
- Conagra’s Turnaround Is Starting to Show Up in the Numbers
- MarketBeat Week in Review – 09/28 – 10/02
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
